Ultra rapid lispro improves postprandial glucose control versus lispro in combination with basal insulin: a study based on CGM in type 2 diabetes in China

What Was Tested

This randomized controlled trial paper looks at Insulin Lispro.

The primary endpoint was to compare the difference in postprandial glucose (PPG) control using CGM between the two groups.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

Subjects with uncontrolled T2D were recruited and randomized 1:2 into the insulin lispro and URLi groups.

Subjects received a consistent basal insulin regimen during the study and self-administered insulin lispro or URLi before each meal throughout the treatment period.

How the Study Was Run

The design is described as randomized, double-blind and parallel-group.

Because people in this Insulin Lispro study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Insulin Lispro.

Groups ran in parallel: each of the participants stayed in one arm throughout.

This was a double-blind, randomized, parallel, prospective, phase 3 study.

Subjects underwent a 3-day continuous glucose monitoring (CGM) at the baseline and endpoint respectively, and then CGM data were analyzed.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Insulin Lispro, Postprandial Period, Blood Glucose, China, Hypoglycemic Agents and Blood Glucose Self-Monitoring.

The authors tagged it with the keywords HbA1c, continuous glucose monitoring, postprandial glucose, postprandial glucose excursions and ultra rapid lispro insulin.

What This Means in Plain Language

The paper is a randomized, double-blind and parallel-group study of Insulin Lispro.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (Frontiers in endocrinology), a journal based in Switzerland.

More context: the Insulin Lispro compound page, all human trials.